Veliparib
Information
- Drug Name
- Veliparib
- Description
- Entry(CIViC)
- 4
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| pancreatic cancer | BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION | B |
Predictive
|
Supports
|
Sensitivity/Response | Rare Germline | 3 | 29338080 | Detail |
| pancreatic cancer | BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION | B |
Predictive
|
Supports
|
Sensitivity/Response | Rare Germline | 3 | 29338080 | Detail |
| pancreatic cancer | BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION | B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Rare Germline | 3 | 29223478 | Detail |
| pancreatic cancer | BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION | B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Rare Germline | 3 | 29223478 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In Phase I study for pancreatic cancer patients GE... | BRCA1 | BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION | Sensitivity | true | CIViC Evidence | detail |
| In Phase I study for pancreatic cancer patients GE... | BRCA2 | BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION | Sensitivity | true | CIViC Evidence | detail |
| Veliparib 400mg bid was administered to patients w... | BRCA1 | BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION | Sensitivity | false | CIViC Evidence | detail |
| Veliparib 400mg bid was administered to patients w... | BRCA2 | BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION | Sensitivity | false | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01149083 | Active, not recruiting | Phase 2 | Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer | June 30, 2010 | June 30, 2025 |
| NCT00588991 | Active, not recruiting | Phase 1 | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | November 28, 2007 | March 7, 2025 |
| NCT00740805 | Active, not recruiting | Phase 1 | Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma | August 18, 2008 | October 7, 2024 |
| NCT03289910 | Active, not recruiting | Phase 2 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | September 24, 2018 | December 21, 2024 |
| NCT00576654 | Active, not recruiting | Phase 1 | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | December 5, 2007 | June 30, 2023 |
| NCT01585805 | Active, not recruiting | Phase 2 | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | May 15, 2012 | December 31, 2024 |
| NCT01351909 | Active, not recruiting | Phase 1 | Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer | May 2, 2011 | March 7, 2025 |
| NCT01366144 | Active, not recruiting | Phase 1 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | June 20, 2011 | March 5, 2025 |
| NCT02152982 | Active, not recruiting | Phase 2/Phase 3 | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | December 15, 2014 | December 15, 2024 |
| NCT01386385 | Active, not recruiting | Phase 1/Phase 2 | Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | June 20, 2011 | December 31, 2024 |
| NCT01434316 | Active, not recruiting | Phase 1 | Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors | November 1, 2011 | July 1, 2024 |
| NCT03581292 | Active, not recruiting | Phase 2 | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | November 6, 2018 | September 22, 2024 |
| NCT01139970 | Active, not recruiting | Phase 1 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | May 21, 2010 | February 22, 2025 |
| NCT02890355 | Active, not recruiting | Phase 2 | FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | September 1, 2016 | March 5, 2025 |
| NCT02631733 | Active, not recruiting | Phase 1 | Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors | May 31, 2017 | July 1, 2024 |
| NCT01012817 | Active, not recruiting | Phase 1/Phase 2 | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | November 3, 2009 | August 30, 2024 |
| NCT02595905 | Active, not recruiting | Phase 2 | Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases | September 15, 2016 | October 31, 2024 |
| NCT01281852 | Completed | Phase 1 | Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | March 14, 2011 | February 11, 2017 |
| NCT01326702 | Completed | Phase 1/Phase 2 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | July 2011 | April 2015 |
| NCT01459380 | Completed | Phase 1 | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | October 11, 2011 | February 11, 2017 |
| NCT01472783 | Completed | Phase 1/Phase 2 | Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation | November 2011 | August 2016 |
| NCT01477489 | Completed | Phase 1 | Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer | January 2012 | October 2017 |
| NCT01506609 | Completed | Phase 2 | Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer | January 23, 2012 | September 2, 2020 |
| NCT01514201 | Completed | Phase 1/Phase 2 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | February 1, 2012 | March 28, 2018 |
| NCT01540565 | Completed | Phase 2 | Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | April 9, 2012 | January 27, 2018 |
| NCT01560104 | Completed | Phase 2 | A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | February 2012 | September 2014 |
| NCT01576172 | Completed | Phase 2 | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | March 30, 2012 | April 23, 2020 |
| NCT01589419 | Completed | Phase 1 | A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer | June 2012 | January 2015 |
| NCT01618357 | Completed | Phase 1 | Pre-Operative Radiation and Veliparib for Breast Cancer | July 22, 2013 | October 17, 2023 |
| NCT01638546 | Completed | Phase 2 | Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | June 2012 | January 2017 |
| NCT01642251 | Completed | Phase 1/Phase 2 | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer | September 28, 2012 | July 2, 2018 |
| NCT01657799 | Completed | Phase 2 | Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer | October 19, 2012 | January 22, 2015 |
| NCT01690598 | Completed | Phase 1/Phase 2 | Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | November 2012 | February 2015 |
| NCT01711541 | Completed | Phase 1/Phase 2 | Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | October 22, 2012 | May 15, 2023 |
| NCT01749397 | Completed | Phase 1 | Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer | December 7, 2012 | November 21, 2019 |
| NCT01818063 | Completed | Phase 2 | Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer | April 25, 2013 | December 10, 2018 |
| NCT01827384 | Completed | Phase 2 | MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations | January 7, 2014 | October 8, 2021 |
| NCT01853306 | Completed | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors | March 18, 2013 | June 29, 2017 |
| NCT01908478 | Completed | Phase 1 | Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer | October 2, 2013 | July 6, 2020 |
| NCT02032277 | Completed | Phase 3 | A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer | April 2, 2014 | November 12, 2020 |
| NCT02033551 | Completed | Phase 1 | A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors | December 2013 | September 2016 |
| NCT02106546 | Completed | Phase 3 | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | April 10, 2014 | November 20, 2019 |
| NCT02163694 | Completed | Phase 3 | A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | July 17, 2014 | January 25, 2024 |
| NCT02264990 | Completed | Phase 3 | Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers | September 30, 2014 | February 21, 2020 |
| NCT02289690 | Completed | Phase 1/Phase 2 | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | October 13, 2014 | April 17, 2019 |
| NCT02305758 | Completed | Phase 2 | Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer | December 2, 2014 | September 22, 2017 |
| NCT02483104 | Completed | Phase 1 | Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | July 2015 | July 2016 |
| NCT02921256 | Completed | Phase 2 | Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | January 11, 2017 | September 20, 2023 |
| NCT00535119 | Completed | Phase 1 | Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer | September 2007 | |
| NCT00770471 | Completed | Phase 1 | ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | July 13, 2009 | March 1, 2012 |
| NCT00892736 | Completed | Phase 1 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | April 20, 2009 | May 19, 2017 |
| NCT00946335 | Completed | Phase 1 | ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors | July 2009 | June 2014 |
| NCT00989651 | Completed | Phase 1 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | October 28, 2009 | April 10, 2020 |
| NCT01017640 | Completed | Phase 1 | Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors | October 2009 | |
| NCT01104259 | Completed | Phase 1 | Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer | July 2010 | April 2017 |
| NCT01123876 | Completed | Phase 1 | Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor | March 2010 | January 2015 |
| NCT01145430 | Completed | Phase 1 | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | June 1, 2010 | |
| NCT01154426 | Completed | Phase 1 | ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors | May 2010 | October 2013 |
| NCT01193140 | Completed | Phase 2 | To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors | July 2010 | November 2011 |
| NCT01199224 | Completed | Phase 1 | To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors | June 2010 | November 2010 |
| NCT01251874 | Completed | Phase 1 | Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer | November 16, 2010 | April 12, 2017 |
| NCT01264432 | Completed | Phase 1 | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | January 1, 2011 | November 15, 2016 |
| NCT01266447 | Completed | Phase 2 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | February 2011 | January 2016 |
| NCT01281150 | Completed | Phase 1 | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | January 2011 | |
| NCT02860819 | Completed | Phase 2 | Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer | August 1, 2016 | February 15, 2021 |
| NCT00387608 | Completed | Phase 1 | ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer | June 2006 | April 2009 |
| NCT02944396 | Completed | Phase 1 | Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) | December 23, 2016 | October 2, 2019 |
| NCT03061188 | Completed | Phase 1 | Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma | May 23, 2017 | August 4, 2020 |
| NCT02985658 | No longer available | Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer | |||
| NCT03123211 | No longer available | Expanded Access to Veliparib | |||
| NCT02412371 | Terminated | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) | April 30, 2015 | August 5, 2019 |
| NCT01282333 | Terminated | Phase 1 | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer | January 2011 | |
| NCT01233505 | Terminated | Phase 1 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | October 2010 | |
| NCT02470585 | Terminated | Phase 3 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | June 29, 2015 | October 5, 2023 |
| NCT03227016 | Unknown status | Phase 1 | Study in Patients With SCLC of Veliparib in Combination With Topotecan | October 2016 | June 2021 |
| NCT02831179 | Withdrawn | Phase 1 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | December 2017 | February 2020 |
| NCT03044795 | Withdrawn | Phase 2 | Response to PARP Inhibitor Predicted by the RAD51 Assay | November 2019 | November 2020 |
| NCT03032614 | Withdrawn | Phase 2 | Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients | September 30, 2017 | April 30, 2020 |
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Poly (ADP-ribose) polymerase (PARP)
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- ABT-888